Floatz logo

TRASTUZUMAB

Neoadjuvant

Union Hospital, Tongji Medical College, Huazhong University of Science and Technologymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Neoadjuvant cohort.

Asset / SponsorPhaseRating
Toripalimab
ZHOU FANGJIAN
Phase 3B
Axitinib
ZHOU FANGJIAN
Phase 3B
Mirvetuximab Soravtansine
AbbVie
Phase 2CCC
Irinotecan
AbbVie
Phase 2CCC
(+)-VINCRISTINE
AbbVie
Phase 2CCC

View all 11 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →